In silico model-based inference: an emerging approach for inverse problems in engineering better medicines.
暂无分享,去创建一个
[1] Stacey D. Finley,et al. Inferring relevant control mechanisms for interleukin‐12 signaling in naïve CD4+ T cells , 2011, Immunology and cell biology.
[2] B. Hemmings,et al. PI3K-PKB/Akt pathway. , 2012, Cold Spring Harbor perspectives in biology.
[3] Jonathan R. Karr,et al. A Whole-Cell Computational Model Predicts Phenotype from Genotype , 2012, Cell.
[4] G. Lahav,et al. Encoding and Decoding Cellular Information through Signaling Dynamics , 2013, Cell.
[5] Lillian L. Siu,et al. Preclinical development of molecular-targeted agents for cancer , 2011, Nature Reviews Clinical Oncology.
[6] Andrew Thomas,et al. The BUGS project: Evolution, critique and future directions , 2009, Statistics in medicine.
[7] Stefano Severi,et al. Comprehensive Analyses of Ventricular Myocyte Models Identify Targets Exhibiting Favorable Rate Dependence , 2014, PLoS Comput. Biol..
[8] David J Klinke,et al. In silico model‐based inference: A contemporary approach for hypothesis testing in network biology , 2014, Biotechnology progress.
[9] Doraiswami Ramkrishna,et al. Mathematics in Chemical Engineering: A 50 Year Introspection (Journal Review) , 2004 .
[10] B. Hemmings,et al. The PI3K-PKB/Akt pathway. , 2015, Cold Spring Harbor perspectives in biology.
[11] K Gadkar,et al. The Type 1 Diabetes PhysioLab® Platform: a validated physiologically based mathematical model of pathogenesis in the non‐obese diabetic mouse , 2010, Clinical and experimental immunology.
[12] D. Klinke,et al. Interlocked positive and negative feedback network motifs regulate β-catenin activity in the adherens junction pathway , 2015, Molecular biology of the cell.
[13] David J. Klinke,et al. An empirical Bayesian approach for model-based inference of cellular signaling networks , 2009, BMC Bioinformatics.
[14] Steffen Klamt,et al. Disentangling the Complexity of HGF Signaling by Combining Qualitative and Quantitative Modeling , 2015, PLoS Comput. Biol..
[15] Julio Saez-Rodriguez,et al. Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks , 2012, BMC Systems Biology.
[16] K. Janes. An analysis of critical factors for quantitative immunoblotting , 2015, Science Signaling.
[17] Jeremy L. Muhlich,et al. Properties of cell death models calibrated and compared using Bayesian approaches , 2013, Molecular systems biology.
[18] V. Grantcharova,et al. Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.
[19] L. Gossage,et al. Targeting Multiple Kinase Pathways: A Change In Paradigm , 2010, Clinical Cancer Research.
[20] David J. Klinke,et al. Quantifying Crosstalk Among Interferon-γ, Interleukin-12, and Tumor Necrosis Factor Signaling Pathways Within a TH1 Cell Model , 2012, Science Signaling.
[21] P Vicini,et al. Systems Pharmacology for Drug Discovery and Development: Paradigm Shift or Flash in the Pan? , 2013, Clinical pharmacology and therapeutics.
[22] Mark A. Girolami,et al. BioBayes: A software package for Bayesian inference in systems biology , 2008, Bioinform..
[23] M. Girolami,et al. Inferring Signaling Pathway Topologies from Multiple Perturbation Measurements of Specific Biochemical Species , 2010, Science Signaling.
[24] Darren J. Wilkinson,et al. CaliBayes and BASIS: integrated tools for the calibration, simulation and storage of biological simulation models , 2010, Briefings Bioinform..
[25] C. Stokes,et al. Preexisting Autoantibodies Predict Efficacy of Oral Insulin to Cure Autoimmune Diabetes in Combination With Anti-CD3 , 2012, Diabetes.
[26] R. Plenge,et al. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. , 2012, Immunity.
[27] Fabian J Theis,et al. High-dimensional Bayesian parameter estimation: case study for a model of JAK2/STAT5 signaling. , 2013, Mathematical biosciences.
[28] Linda J. Broadbelt,et al. Construction of a mechanistic model of Fischer–Tropsch synthesis on Ni(1 1 1) and Co(0 0 0 1) surfaces , 1999 .
[29] Thomas Thorne,et al. Model selection in systems and synthetic biology. , 2013, Current opinion in biotechnology.
[30] F. Baran-Marszak,et al. STAT3 inhibitors for cancer therapy , 2013, JAK-STAT.
[31] J. Pearl. Causality: Models, Reasoning and Inference , 2000 .
[32] Stacey D. Finley,et al. Timescale analysis of rule‐based biochemical reaction networks , 2012, Biotechnology progress.
[33] Ulrik B. Nielsen,et al. Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 , 2012, Molecular Cancer Therapeutics.
[34] Eduardo D. Sontag,et al. Inferring dynamic architecture of cellular networks using time series of gene expression, protein and metabolite data , 2004, Bioinform..
[35] Ioannis G. Kevrekidis,et al. Matrices are forever: On applied mathematics and computing in chemical engineering , 1995 .
[36] K. Bischoff,et al. The delplot technique: a new method for reaction pathway analysis , 1990 .
[37] M R Birtwistle,et al. Mechanistic Vs. Empirical Network Models of Drug Action , 2013, CPT: pharmacometrics & systems pharmacology.
[38] D. Ramkrishna,et al. 2 Mathematics in Chemical Engineering , 2009 .
[39] X. Tian,et al. JAK-STAT3 and somatic cell reprogramming , 2013, JAK-STAT.
[40] E. Jaynes. Probability theory : the logic of science , 2003 .
[41] Melvin E. Andersen,et al. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[42] E. Estey,et al. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. , 2010, Blood.
[43] Matthias von Herrath,et al. Virtual Optimization of Nasal Insulin Therapy Predicts Immunization Frequency to Be Crucial for Diabetes Protection , 2010, Diabetes.
[44] Gordon Ellis,et al. Grand challenges for engineering , 2009, IEEE Engineering Management Review.
[45] Birgit Schoeberl,et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. , 2010, Cancer research.